Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBINASDAQ:CGTXNYSE:CVMNASDAQ:CYTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsCGTXCognition Therapeutics$0.30+15.6%$0.33$0.22▼$2.54$16.09M0.752.73 million shs1.52 million shsCVMCEL-SCI$2.43-1.2%$5.08$1.98▼$66.60$7.37M0.2775,875 shs129,134 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57527,459 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%CGTXCognition Therapeutics+15.61%+7.14%+1.04%-32.07%-83.78%CVMCEL-SCI-1.22%+4.74%-3.19%-66.25%-93.36%CYTHCyclo Therapeutics0.00%0.00%0.00%+3.39%-38.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIBrickell BiotechN/AN/AN/AN/AN/AN/AN/AN/ACGTXCognition Therapeutics3.1032 of 5 stars3.55.00.00.00.61.71.3CVMCEL-SCI0.0654 of 5 stars0.02.00.00.00.00.00.6CYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIBrickell Biotech 0.00N/AN/AN/ACGTXCognition Therapeutics 3.00Buy$5.631,775.00% UpsideCVMCEL-SCI 0.00N/AN/AN/ACYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideCurrent Analyst Ratings BreakdownLatest BBI, CGTX, CVM, and CYTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIBrickell Biotech$4.64M0.00N/AN/A$9.75 per share0.00CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/ACYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIBrickell Biotech-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/ACGTXCognition Therapeutics-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/ACYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/ALatest BBI, CGTX, CVM, and CYTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIBrickell BiotechN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIBrickell BiotechN/A6.366.36CGTXCognition TherapeuticsN/A2.092.09CVMCEL-SCI0.661.071.09CYTHCyclo TherapeuticsN/A0.170.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIBrickell BiotechN/ACGTXCognition Therapeutics43.35%CVMCEL-SCI12.08%CYTHCyclo Therapeutics68.55%Insider OwnershipCompanyInsider OwnershipBBIBrickell Biotech4.53%CGTXCognition Therapeutics14.40%CVMCEL-SCI9.93%CYTHCyclo Therapeutics29.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIBrickell Biotech162.87 million2.74 millionNot OptionableCGTXCognition Therapeutics2061.99 million53.07 millionNot OptionableCVMCEL-SCI433.03 million64.67 millionOptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataBBI, CGTX, CVM, and CYTH HeadlinesRecent News About These CompaniesCyclo Therapeutics shareholders approve merger with Rafael HoldingsMarch 26, 2025 | uk.investing.comIs Cyclo Therapeutics, Inc. (CYTH) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.com10 Best Micro Cap Stocks to Buy NowMarch 6, 2025 | insidermonkey.comCYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTHFebruary 20, 2025 | businesswire.comCyclo Therapeutics reports promising NPC1 treatment findingsFebruary 7, 2025 | msn.comCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)February 7, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of ShareholdersJanuary 24, 2025 | stockhouse.com$TOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - CYTH, ALVR, WMPN, OMCJanuary 24, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: The M&A Class Action Firm Continues Its Merger Investigation - AUB, CYTH, PDCO, SKGRDecember 20, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of ShareholdersDecember 20, 2024 | prnewswire.comRafael Holdings, Inc.: Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsDecember 11, 2024 | finanznachrichten.deNiemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBioNovember 21, 2024 | globenewswire.comCyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 15, 2024 | finance.yahoo.comCyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue EstimatesNovember 14, 2024 | zacks.comPacira BioSciences Appoints Shawn Cross As CFOOctober 21, 2024 | markets.businessinsider.comCyclo TherapeuticsSeptember 14, 2024 | thepharmaletter.comMaxim Group Downgrades Cyclo Therapeutics (CYTH)August 29, 2024 | msn.comCYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTHAugust 27, 2024 | businesswire.comHC Wainwright & Co. Downgrades Cyclo Therapeutics (CYTH)August 24, 2024 | msn.comShareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBI, CGTX, CVM, and CYTH Company DescriptionsBrickell Biotech NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Cognition Therapeutics NASDAQ:CGTX$0.30 +0.04 (+15.61%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.31 +0.01 (+4.67%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.CEL-SCI NYSE:CVM$2.43 -0.03 (-1.22%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.62%) As of 06/24/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
